Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway

Su,Chin-Cheng

doi:10.3892/ijmm.2018.3407

Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway

Authors:
- Chin-Cheng Su
View Affiliations

Affiliations: Tumor Research Center of Integrative Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan, R.O.C.
Published online on: January 19, 2018 https://doi.org/10.3892/ijmm.2018.3407
Pages: 2389-2396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The RAS/RAF/MEK/ERK pathway is one of the most frequently dysregulated kinase cascades in human cancer, that facilitate the proliferation and survival of cancers driven by growth factor receptors. Tanshinone IIA (Tan-IIA) was extracted from Danshen (Salviae Miltiorrhizae Radix). Tan-IIA inhibition of the proliferation of gastric cancer are well documented, but the molecular mechanisms of Tan-IIA inhibition of gastric cancer have not been well elucidated. We evaluated the protein expression of vascular epidermal growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2), Ras, Raf, MEK, ERK, PARP, caspase-3 and β-actin in AGS cells by western blotting. The results showed that AGS cells treated with Tan-IIA upregulated the protein expression of PARP and caspase-3 but decreased VEGFR, HER2, Ras, Raf, MEK and ERK time- and dose-dependently. These findings demonstrated that Tan-IIA inhibited human gastric cancer AGS cells; one of the molecular mechanisms may be through decreasing the protein expression of VEGFR and HER2, then blocking the Ras/Raf/MEK/ERK pathway to induce the activation of PARP and caspase-3 to induce apoptosis.

View Figures

View References

1	Che AJ, Zhang JY, Li CH, Chen XF, Hu ZD and Chen XG: Separation and determination of active components in Radix Salviae miltiorrhizae and its medicinal preparations by nonaqueous capillary electrophoresis. J Sep Sci. 27:569–575. 2004. View Article : Google Scholar : PubMed/NCBI
2	Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lin R, Wang WR, Liu JT, Yang GD and Han CJ: Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J Ethnopharmacol. 108:217–222. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841. 2003. View Article : Google Scholar : PubMed/NCBI
5	Jang SI, Kim HJ, Kim YJ, Jeong SI and You YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: Possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol. 542:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
6	Li W, Li J, Ashok M, Wu R, Chen D, Yang L, Yang H, Tracey KJ, Wang P, Sama AE, et al: A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol. 178:3856–3864. 2007. View Article : Google Scholar : PubMed/NCBI
7	Su CC and Lin YH: Tanshinone IIA downregulates the protein expression of ErbB-2 and upregulates TNF-α in colon cancer cells in vitro and in vivo. Int J Mol Med. 22:847–851. 2008.PubMed/NCBI
8	Su CC and Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med. 22:357–361. 2008.PubMed/NCBI
9	Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
10	Cheng CY and Su CC: Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Mol Med Rep. 3:645–650. 2010.
11	Cheng CY and Su CC: Tanshinone IIA inhibits Hep-J5 cells by increasing calreticulin, caspase 12 and GADD153 protein expression. Int J Mol Med. 26:379–385. 2010.PubMed/NCBI
12	Yan MY, Chien SY, Kuo SJ, Chen DR and Su CC: Tanshinone IIA inhibits BT-20 human breast cancer cell proliferation through increasing caspase 12, GADD153 and phospho-p38 protein expression. Int J Mol Med. 29:855–863. 2012.PubMed/NCBI
13	Huang CY, Chiu TL, Kuo SJ, Chien SY, Chen DR and Su CC: Tanshinone IIA inhibits the growth of pancreatic cancer BxPC3 cells by decreasing protein expression of TCTP, MCL1 and Bcl-xL. Mol Med Rep. 7:1045–1049. 2013. View Article : Google Scholar : PubMed/NCBI
14	Su CC: Tanshinone IIA could inhibit pancreatic cancer BxPC-3 cells through increasing PERK, ATF6, caspase-12 and CHOP expression to induce apoptosis. J Biomed Sci Eng. 8:149–159. 2015. View Article : Google Scholar
15	Yuen JS and Macaulay VM: Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets. 12:589–603. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
17	Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
18	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
19	McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, et al: Therapeutic resistance resulting from mutations in Raf/MEK/ERK and I3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI
20	Su CC: Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl 1 and Bcl xL and increasing Bax and CHOP protein expression. Int J Mol Med. 34:1661–1668. 2014. View Article : Google Scholar : PubMed/NCBI
21	Su CC: Tanshinone IIA inhibits gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but reducing p-ERK, CDC2 and cyclin B1 expression. Anticancer Res. 34:7097–7110. 2014.PubMed/NCBI
22	Hou J, He J, Jin X, Hu T and Zhang Y: Study on optimisation of extraction process of tanshinone IIA and its mechanism of induction of gastric cancer SGC7901 cell apoptosis. Afr J Tradit Complement Altern Medicines. 10:456–458. 2013. View Article : Google Scholar
23	Xu M, Cao FL, Li NY, Liu YQ, Li YP and Lv CL: Tanshinone IIA reverses the malignant phenotype of SGC7901 gastric cancer cells. Asian Pac J Cancer Prev. 14:173–177. 2013. View Article : Google Scholar : PubMed/NCBI
24	Dong X, Dong J, Peng G, Hou X and Wu G: Growth-inhibiting and apoptosis-inducing effects of Tanshinone II A on human gastric carcinoma cells. J Huazhong Univ Sci Technolog Med Sci. 27:706–709. 2007. View Article : Google Scholar
25	Kranenburg O, Gebbink MF and Voest EE: Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta. 1654:23–37. 2004.PubMed/NCBI
26	Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 15:158–163. 2003. View Article : Google Scholar : PubMed/NCBI
27	Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A and van Bergen en Henegouwen P: The epidermal growth factor. Cell Biol Int. 19:413–430. 1995. View Article : Google Scholar : PubMed/NCBI
28	Cary LA, Han DC and Guan JL: Integrin-mediated signal transduction pathways. Histol Histopathol. 14:1001–1009. 1999.PubMed/NCBI
29	Schlesinger TK, Fanger GR, Yujiri T and Johnson GL: The TAO of MEKK. Front Biosci. 3:D1181–D1186. 1998. View Article : Google Scholar : PubMed/NCBI
30	Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
31	Rubinfeld H and Seger R: The ERK cascade: A prototype of MAPK signaling. Mol Biotechnol. 31:151–174. 2005. View Article : Google Scholar : PubMed/NCBI